Skip to main content

Bayer Faces $1.56B Verdict in Latest Roundup Trial Loss

Bayer Faces $1.56B Verdict in Latest Roundup Trial Loss

Introduction

A Missouri jury has ordered Bayer to pay $1.56 billion to four plaintiffs who asserted that the company's Roundup weedkiller led to injuries, including cancer.

This verdict may increase investor pressure on Bayer to reconsider its legal strategy. The jury found that Bayer's Monsanto business was responsible for negligence, design defects, and failure to warn about the potential dangers of Roundup.

The plaintiffs from New York and California were granted a total of $61.1 million in compensatory damages and $500 million each in punitive damages. They were diagnosed with non-Hodgkin lymphoma, which they claimed resulted from using Roundup on their properties. One plaintiff's wife was awarded $100,000 for the harm she allegedly suffered due to her husband's disease.

The punitive damages might be reduced on appeal as they exceed U.S. Supreme Court guidance. Bayer maintains that decades of studies demonstrate the safety of Roundup and its active ingredient, glyphosate, for human use.

This verdict marks the fourth consecutive legal loss for Bayer, following nine consecutive trials where the company was found not liable. Earlier, Union Investment, one of Bayer's top 10 shareholders, urged the company to explore settlement options with plaintiffs.

Bayer contends that it has strong arguments to overturn the recent verdicts on appeal. The company argues that courts in these trials allowed plaintiffs to misrepresent the European Union's glyphosate renewal process and the safety assessment by the U.S. Environmental Protection Agency.

Despite settling most Roundup cases in 2020 for up to $10.9 billion, approximately 50,000 claims remain pending out of around 165,000 claims against Bayer. These claims stem from personal injuries allegedly caused by Roundup, acquired by Bayer through its $63 billion purchase of Monsanto in 2018.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!